YOU ARE HERE: LAT HomeCollectionsAntibodies


May 20, 1988 | THOMAS H. MAUGH II, Times Science Writer
For the first time, researchers have been able to use genetic engineering techniques to produce key parts of disease-fighting antibodies in bacterial cells, a Santa Monica-based biotechnology company said in a report published today. Biologists at International Genetic Engineering Inc. (Ingene) used the technique to produce an antibody fragment that binds specifically to human colon cancer cells.
October 11, 2013 | By Karen Ravn
Fall is in the air and so, alas, are zillions of grains of weed pollen, sailing hither and yon, high and low, far and wide. These guarantee an abundance of new little weeds next year - and an abundance of sniffy, sneezy, wheezy people right now, namely those unfortunate souls who have an allergy to pollen. Pollen allergy is often called "hay fever," although it doesn't cause fever and its only connection with hay is that it inflicts its woes at hay-harvesting time. The name "seasonal allergic rhinitis" - where "rhinitis" refers to an inflamed nose - is more accurate if less evocative.
November 27, 1985 | NANCY WRIDE, Times Staff Writer
The mother of an 11-year-old El Toro boy sought an injunction against the Saddleback Unified School District on Tuesday, claiming that he was expelled from school after it was discovered that he has an AIDS-linked antibody in his blood. School district officials said the boy had never been expelled but was being tutored at home at his mother's request.
November 2, 1987
Dr. Leroy Hood, a Caltech molecular geneticist, in September was one of three scientists to win the prestigious Lasker Basic Medical Research Award for helping explain how the immune system creates an almost endless variety of antibodies to protect the human body from foreign invaders. The immune system is believed crucial to curing many of man's diseases, a fact reflected in the number of Nobel prizes granted in this field.
September 6, 1991 | From Times Staff and Wire Reports
Up to 40% of operations to open clogged arteries fail when the vessels develop new blockages. Now a laboratory study with rats shows that an antibody may prevent this problem, offering new hope for human heart disease patients. Researchers at the University of Washington report that they have used an antibody extracted from goats to keep arteries clear in rats that underwent an operation commonly used in human heart disease to open up blocked vessels.
October 30, 1995 | From Times staff and wire reports
Researchers studying the AIDS virus report in the journal Nature that it could remain infectious even when surrounded by neutralizing antibodies that would normally destroy it. A team at Virginia Commonwealth University examined follicular dendritic cells (FDCs) in the lymph nodes where large amounts of HIV, the AIDS virus, congregate.
In a development that could lead to major improvements in the treatment of autoimmune diseases, cancer, AIDS and organ rejection in humans, two California companies report today that they have been able to genetically engineer mice so that they produce human antibodies. Mouse cells that produce these antibodies can then be grown in laboratory vats to produce large amounts of so-called monoclonal antibodies that, when given to patients, can attack and destroy diseased cells.
February 11, 2010 | By Thomas H. Maugh II
Three years after the U.S. blood-banking industry recommended against transfusing plasma from female donors because of a potentially life-threatening antibody reaction, researchers have found that plasma from women may actually be better, not worse, for heart surgery patients. In a study of patients treated before the new guidelines were implemented, those receiving plasma from women were only half as likely to suffer lung complications from the surgery and were 45% less likely to be hospitalized or die in the 10 days after surgery, a Duke University Medical Center team reported.
In a major advance against a leading cause of death, a national study has found that a genetically engineered medication may significantly reduce the death rate of patients with severe bacterial infections of their bloodstreams. The experimental drug, known as HA-1A, is a human monoclonal antibody, a man-made form of a specialized immune system molecule designed to protect the body against disease. However, the medication remains unavailable to most patients who might benefit from it. The U.S.
July 9, 2010 | By Thomas H. Maugh II, Los Angeles Times
An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday. Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus. HIV, the virus that causes AIDS, is notoriously mutable, changing the composition of proteins on its surface with ease to escape pressure from the immune system.
Los Angeles Times Articles